Articles tagged with Glaucoma
A team of investigators has identified a new candidate gene for primary open angle glaucoma (POAG), the most common form of eye disorder. The gene, ADAMTS10, is involved in processing extracellular matrix and may play a role in regulating aqueous humor outflow.
A study of 3,939 participants found that obesity was associated with higher eye pressure and a lower risk of open-angle glaucoma in women. The authors suggest that high estrogen levels and hormone therapy may be protective against open-angle glaucoma in obese women.
Researchers at the University of Arizona have developed a new hand-held instrument to detect glaucoma earlier and with greater accuracy. The device uses micro-force sensors and math-based procedures to gently rub the eyelid, measuring intraocular pressure without the need for painful eye drops or sterilized sensors.
Researchers discovered a unique class of cells called astrocytes that contribute to visual blinding in glaucoma, as well as abnormal forms of gamma synuclein. The study's findings suggest a biological process similar to Parkinson's disease unfolds at the optic nerve head.
Two studies published in the journal Ophthalmology suggest that omega-3 rich fish and seafood consumption may help prevent advanced age-related macular degeneration (AMD) in seniors. Additionally, a new test called pattern electroretinogram (PERGLA) shows promise for early detection of glaucoma by measuring retinal ganglion cell function.
A study of 3,015 individuals found that corneal arcus is associated with higher intraocular pressure and thicker corneas. Participants with corneal arcus were more likely to have high eye pressure but not glaucoma.
A new study shows that using a more expensive but accurate tool to test for glaucoma can reduce unnecessary referrals by nearly two thirds. This could alleviate pressure on hospitals and lower costs for patients.
Researchers studied genetic risk factors for age-related macular degeneration (AMD) and found that patients carrying specific genes were more likely to respond to anti-VEGF therapy. Genetic screening may improve glaucoma care by identifying markers for congenital and primary open angle glaucoma.
Researchers found a link between low blood pressure at night and an increased risk of glaucoma in patients with migraine. Mobile devices like iPhones can also be used to evaluate ophthalmic images with high consistency, revolutionizing digital eye care.
A study of 216 patients with open-angle glaucoma found that older patients and those with abnormal anticardiolin antibodies experienced faster visual field decline. Reducing intraocular pressure modestly slowed this decline, particularly in younger patients.
Dr. Yücel's discovery dispels the longstanding assumption that the eye has no lymphatics, leading to new treatments for glaucoma and eye tumours. The find also refutes the idea that the eye is not connected to the body's immune system.
Researchers have identified a unique set of proteins in glaucomatous eyes that may help diagnose and treat the condition. The protein profile is linked to changes in the trabecular meshwork, which could lead to new therapeutic strategies.
Childhood glaucoma is a rare condition often associated with significant visual loss. A study found an incidence of 2.29 per 100,000 residents younger than 20 years, with acquired glaucoma being the most common type.
Researchers have developed contact lenses loaded with vitamin E that can deliver more medication for glaucoma and other diseases to the eye, increasing treatment duration by about 100 times. Vitamin E's ant-oxidant properties also provide UV protection.
Scientists have developed a new diagnostic method using Raman spectroscopy to detect biochemical changes in retinal cells, revealing the presence of glaucoma. The test detected glaucomatous changes with 90% accuracy in animal retinal tissue testing.
Early treatment reduces glaucoma risk in high-risk individuals, but delaying treatment may not offer significant benefits for those at low risk. An individualized assessment can aid patients and clinicians in making informed treatment decisions.
Researchers at Vanderbilt University Medical Center have found that the first sign of injury in glaucoma occurs in the brain, where neuronal communication with the optic nerve is compromised. This discovery offers new insights into the disease and potential treatment targets.
A study of 21,506 glaucoma patients found that those taking glaucoma medications had a 74% reduced risk of death over a 4-year period. The association was observed for both single-agent and combination use of glaucoma medications.
Researchers aim to improve methods for screening and testing glaucoma, a disease affecting 70 million people worldwide. The study will focus on optimizing perimetry testing and developing new statistical methods to compare different clinical measures.
A study found that anti-VEGF treatment for wet age-related macular degeneration can lead to increased intraocular pressure in patients without a family history of glaucoma. A new low-cost vision screening method, using an auto-refractor and pre-made eyeglasses, has shown promise in improving vision for millions in developing countries.
Glaucoma clinics face challenges in providing follow-up care to patients from diverse ethnic backgrounds, with long wait times and interpreter issues cited as major barriers. To address these issues, researchers suggest streamlining appointment procedures and resolving wait time and language obstacles.
Researchers at University of Toronto have discovered a previously unidentified form of circulation within the human eye, which may provide important new insights into glaucoma. The discovery overthrows the idea that the eye is an immune privileged site due to the lack of lymphatics.
A recent study has identified gene variants for glaucoma in a black population, which could lead to future treatments or a cure for the disease. The finding is significant as it explains nearly one-third of the genetic risk for glaucoma and could provide a more accurate and earlier diagnosis.
Glaucoma surgical procedures have been increasing, but Medicare payments for the procedures have been decreasing. The analysis found that average payments for trabeculoplasties decreased over time, while annual payments for cyclodestructive procedures and shunt-related procedures increased.
Corneal transplant failures were found to be four times higher in patients with corneal edema or Fuchs' dystrophy compared to those without. Glaucoma patients who take medications alone have a 29% failure rate, highlighting the importance of adherence to treatment plans.
A new study analyzed dietary factors and found that a combination of key nutrients and low-glycemic index foods can reduce age-related macular degeneration (AMD) risks. Additionally, research highlights the cost-effectiveness of glaucoma treatment in improving vision quality and quality of life.
Four young researchers under 45 received the 2009 ARVO-AFER/Merck Innovative Ophthalmology Research Award for their groundbreaking research on glaucoma and back-of-the-eye diseases. The award recognizes outstanding investigative work that could lead to meaningful improvements in patients' lives.
A team of scientists led by Dr. Michael Walter discovered that WDR36 gene variations affect cell function only when combined with changes in another gene, STI1. This finding explains why some people with WDR36 gene variations get glaucoma while others don't.
Researchers are exploring various factors that contribute to glaucoma, including the role of glial cells, mitochondria, and immune response. The report highlights potential approaches for neuroprotection, such as targeting mitochondrial events and manipulating the immune system to repair neural tissue.
Age-related Macular Degeneration (AMD) can be slowed down with a balanced diet high in micronutrients, vitamins and antioxidants. Increasing fruit and vegetable intake could add up to 20% extra time for AMD sufferers before degeneration sets in.
A study found that glaucoma is associated with slower spoken reading and increased reading impairment in older adults. The research tested 1,154 individuals and found that those with bilateral glaucoma read 29 words per minute slower than those without the condition and had roughly twice the odds of reading impairment.
Researchers at Mayo Clinic have identified associations between obstructive sleep apnea (OSA) and various eye diseases, including primary open-angle glaucoma, normal-tension glaucoma, flopsy eyelid syndrome, nonarteritic anterior ischemic optic neuropathy, and papilledema. Early diagnosis and treatment are crucial for patients with OSA.
A study found a correlation between optic nerve damage in glaucoma patients and significant carotid artery narrowing, potentially increasing stroke risk. Additionally, a survey on religious beliefs and fasting reveals that adherence to faith-related taboos can impact patient compliance with ocular treatment.
Researchers at the University of Alberta have discovered how copy number variations contribute to pediatric glaucoma, a disease that can lead to blindness. The study's findings may help improve detection and treatment of childhood glaucoma, paving the way for earlier intervention and better outcomes.
The article discusses a global summit of leading glaucoma specialists who gathered to discuss key needs and opportunities in advancing therapies for patients. The summit highlighted the need to advance beyond traditional IOP-lowering therapies and explore new approaches, including innovative drug delivery systems and novel biomarkers.
Researchers at UC Davis have created smart contact lenses that can measure eye pressure and dispense medication. These contact lenses, made with a new material, could help doctors better understand glaucoma and improve patient treatment.
A large-scale Medicare study evaluated the outcomes of incisional surgeries used to reduce eye pressure in patients with glaucoma. The study found that while surgeries were effective for most patients, rates of severe outcomes and progression to low vision or blindness were higher for those who received implantation of a glaucoma drain...
A study found that glaucoma patients with poor health literacy have lower understanding of the condition, miss more appointments, and experience faster visual field loss. The authors emphasize the need for culturally and linguistically appropriate communication to improve patient compliance with medications and treatment.
Two studies shed new light on eye health issues: the role of antioxidant supplements in preventing cataract development and their relationship to mortality. Glaucoma research also explores the link between cerebrospinal fluid pressure and optic nerve damage, revealing a potential contributor to glaucoma's progression.
A study published in Archives of Ophthalmology found that black patients with diagnosed and treated glaucoma have a higher risk of cardiovascular death. The research suggests that this increased risk may be due to the use of certain medications used to treat glaucoma.
Researchers have identified a key role for a glaucoma gene, sFRP1, in the development of the disease, which causes high pressure in the eye. Over-expression of this gene disrupts the WNT-signaling pathway, leading to elevated intraocular pressure and vision loss.
A new study reveals that increased expression of the protein sFRP-1, an inhibitor of cell signaling through WNT proteins, is responsible for elevated intraocular pressure in individuals with glaucoma. Restoring WNT signaling may offer a novel treatment approach to manage the disease.
Scientists discovered that HOXA11, a homeobox gene, is essential for the development of uterosacral ligaments, which are weakened in women with pelvic organ prolapse. In another study, researchers found that increased expression of the WNT antagonist sFRP-1 contributes to elevated intraocular pressure in glaucoma patients.
The management of glaucoma costs the US healthcare system approximately $2.5 billion per year, with glaucoma medications accounting for 38-52% of direct costs. Non-selective ß-blockers remain the most inexpensive class of glaucoma medications, while brand-name ß-blockers are consistently more expensive than their generic counterparts.
Research found that glaucoma patients with fluctuating eye pressure have worse visual fields after three months and 13 years, highlighting the importance of reducing long-term IOP fluctuations. The study suggests that 'IOP modulation' rather than reduction is a more effective treatment approach for stabilizing vision.
Scientists identified two SNPs in the LOXL1 gene that confer high risk of exfoliation glaucoma, a devastating eye disease. The variants account for virtually all cases of the condition, offering a promising target for therapy and potential elimination of the disease.
Researchers at Purdue University developed miniature devices to predict and prevent epileptic seizures by detecting neural signals in the brain. The system records data from 1,000 channels, enabling better prediction of seizure onset. A nanotech sensor for glaucoma treatment is also being developed.
Researchers have found a clear link between Alzheimer's disease and glaucoma, with key proteins implicated in both conditions. Novel drugs targeting these proteins may be used to treat glaucoma, opening up new avenues for treatment beyond intraocular pressure control.
Researchers at Iowa State University have successfully treated rats with blindness caused by glaucoma using a new technique involving bone marrow-derived stem cells. The experimental treatment aims to move to human trials and potentially benefit millions of people affected by the condition.
Researchers have developed a unique nanoparticle that can safely deliver a compound to the eye, blocking an enzyme that contributes to glaucoma. This non-toxic tool offers high penetration rates and little patient discomfort, making it a promising treatment option.
Researchers found a strong association between high arterial pulse pressure and high-tension open-angle glaucoma. Individuals with high pulse pressure were more likely to develop the condition, possibly due to increased carotid arterial stiffness.
A recent ARVO study found that nearly one-third of older Americans diagnosed with primary open angle glaucoma are not treated medically or surgically for the condition. The study revealed that despite increasingly effective therapies, many patients are not benefiting from consistent glaucoma treatment.
Researchers at Stanford University School of Medicine found a new syndrome occurring in the Chinese population that may not lead to severe vision loss or blindness. The condition affects young and middle-aged individuals with normal eye pressure and nearsightedness.
Researchers at Dalhousie University found that glaucoma patients are over three times more likely to experience falls and six times more likely to be involved in motor vehicle accidents. Impaired useful field of view is the strongest risk factor for these accidents.
A new study suggests that targeting tumor necrosis factor-alpha (TNF-alpha) may help prevent optic-nerve damage in glaucoma patients. Researchers found that blocking TNF-alpha's action with an antibody prevented loss of oligodendrocytes and retinal ganglion cells when intraocular pressure was raised.
Researchers developed a model to identify high-risk patients for developing glaucoma. The model uses five key risk factors and can predict an individual's risk of developing glaucoma over the next five years. This tool will help physicians determine which patients to treat aggressively and inform patients about their treatment options.
Researchers gathered at the ARVO/Pfizer Ophthalmics Research Institute conference to discuss the current understanding of aqueous outflow pathways. The study aims to identify key unanswered research questions and explore new ideas for controlling high eye pressure in glaucoma patients.
Intraocular pressure increased in 90% of weightlifters during exercises, with higher pressures observed when holding breath. The study suggests that weightlifting could be a potential risk factor for normal-tension glaucoma.
A 20-year study found that type 2 diabetes is associated with primary open angle glaucoma (POAG), a leading cause of blindness. Researchers observed over 76,000 women and found a positive association between type 2 diabetes and POAG, regardless of duration.
A global study estimates that 60.5 million people will have glaucoma by 2010, with 3 out of 4 cases being open angle glaucoma. By 2020, this number is projected to reach 80 million, mostly affecting women and people from Asia. The disease will also increase rapidly in India, causing significant blindness worldwide.